GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (FRA:VTFN) » Definitions » EV-to-Revenue

Vitrolife AB (FRA:VTFN) EV-to-Revenue : 7.50 (As of May. 26, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Vitrolife AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vitrolife AB's enterprise value is €2,283.2 Mil. Vitrolife AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €304.5 Mil. Therefore, Vitrolife AB's EV-to-Revenue for today is 7.50.

The historical rank and industry rank for Vitrolife AB's EV-to-Revenue or its related term are showing as below:

FRA:VTFN' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.32   Med: 11.76   Max: 42.45
Current: 7.58

During the past 13 years, the highest EV-to-Revenue of Vitrolife AB was 42.45. The lowest was 3.32. And the median was 11.76.

FRA:VTFN's EV-to-Revenue is ranked worse than
76.65% of 831 companies
in the Medical Devices & Instruments industry
Industry Median: 3.24 vs FRA:VTFN: 7.58

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Vitrolife AB's stock price is €15.95. Vitrolife AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €2.25. Therefore, Vitrolife AB's PS Ratio for today is 7.09.


Vitrolife AB EV-to-Revenue Historical Data

The historical data trend for Vitrolife AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB EV-to-Revenue Chart

Vitrolife AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.07 18.08 46.24 8.31 7.86

Vitrolife AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.20 8.78 6.15 7.86 8.10

Competitive Comparison of Vitrolife AB's EV-to-Revenue

For the Medical Devices subindustry, Vitrolife AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrolife AB's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's EV-to-Revenue falls into.



Vitrolife AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vitrolife AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2283.169/304.467
=7.50

Vitrolife AB's current Enterprise Value is €2,283.2 Mil.
Vitrolife AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €304.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vitrolife AB  (FRA:VTFN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vitrolife AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.95/2.249
=7.09

Vitrolife AB's share price for today is €15.95.
Vitrolife AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.25.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vitrolife AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vitrolife AB (FRA:VTFN) Business Description

Traded in Other Exchanges
Address
Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive advanced support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction.

Vitrolife AB (FRA:VTFN) Headlines

No Headlines